Romain Guièze

Romain Guièze

Auto-generated profile, based on publicly available information

Romain Guièze

University Hospital of Clermont‐Ferrand and Université Clermont Auvergne Clermont‐Ferrand France

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2023 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
EPErin M. Parry
Erin M. Parry
ILIgnaty Leshchiner
Ignaty Leshchiner
RGRomain Guièze
Romain Guièze
CJConnor Johnson
Connor Johnson
ETEugen Tausch
Eugen Tausch
CWCatherine J. Wu
Catherine J. Wu

1 June 2014 in Clinical Nutrition
Verified
Journal Article
Closed access
RGRomain Guièze
Romain Guièze
RLRichard Lemal
Richard Lemal
ACAurélie Cabrespine
Aurélie Cabrespine
EHEric Hermet
Eric Hermet
OTOlivier Tournilhac
Olivier Tournilhac
CBCorinne Bouteloup
Corinne Bouteloup

15 November 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
SCStephen Jun Fei Chong
Stephen Jun Fei Chong
FZFen Zhu
Fen Zhu
ODOlga Dashevsky
Olga Dashevsky
RMRin Mizuno
Rin Mizuno
JLJolin X.H. Lai
Jolin X.H. Lai
MDMatthew S. Davids
Matthew S. Davids
The B cell leukemia/lymphoma 2 (BCL-2) inhibitor venetoclax is effective in chronic lymphocytic leukemia (CLL); however, resistance may develop over time. Other lymphoid malignancies such as diffuse large B cell lymphoma (DLBCL) are frequently intrinsically resistant to venetoclax. Although genomic resistance mechanisms such as BCL2 mutations have been described, this probably only explains a subset of resistant cases. Using 2 complementary functional precision medicine techniques — BH3 profiling and high-throughput kinase activity mapping — we found that hyperphosphorylation of BCL-2 family proteins, including antiapoptotic myeloid leukemia 1 (MCL-1) and BCL-2 and proapoptotic BCL-2 agonist of cell death (BAD) and BCL-2 associated X, apoptosis regulator (BAX), underlies functional mechanisms of both intrinsic and acquired resistance to venetoclax in CLL and DLBCL. Additionally, we provide evidence that antiapoptotic BCL-2 family protein phosphorylation altered the apoptotic protein interactome, thereby changing the profile of functional dependence on these prosurvival proteins. Targeting BCL-2 family protein phosphorylation with phosphatase-activating drugs rewired these dependencies, thus restoring sensitivity to venetoclax in a panel of venetoclax-resistant lymphoid cell lines, a resistant mouse model, and in paired patient samples before venetoclax treatment and at the time of progression.

25 January 2021 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
FBFlorian Bouclet
Florian Bouclet
ACAnne Calleja
Anne Calleja
MDMarie-Sarah Dilhuydy
Marie-Sarah Dilhuydy
LVLauren Véronèse
Lauren Véronèse
BPBruno Pereira
Bruno Pereira
RGRomain Guièze
Romain Guièze

6 December 2022 in Blood Cancer Discovery
Verified
Journal Article
Closed access
PDF file
EHElisa Ten Hacken
Elisa Ten Hacken
TSTomasz Sewastianik
Tomasz Sewastianik
SYShanye Yin
Shanye Yin
GHGabriela Brunsting Hoffmann
Gabriela Brunsting Hoffmann
MGMichaela Gruber
Michaela Gruber
CWCatherine J. Wu
Catherine J. Wu
Transformation to aggressive disease histologies generates formidable clinical challenges across cancers, but biological insights remain few. We modeled the genetic heterogeneity of chronic lymphocytic leukemia (CLL) through multiplexed in vivo CRISPR-Cas9 B-cell editing of recurrent CLL loss-of-function drivers in mice and recapitulated the process of transformation from indolent CLL into large cell lymphoma [i.e., Richter syndrome (RS)]. Evolutionary trajectories of 64 mice carrying diverse combinatorial gene assortments revealed coselection of mutations in Trp53, Mga, and Chd2 and the dual impact of clonal Mga/Chd2 mutations on E2F/MYC and interferon signaling dysregulation. Comparative human and murine RS analyses demonstrated tonic PI3K signaling as a key feature of transformed disease, with constitutive activation of the AKT and S6 kinases, downmodulation of the PTEN phosphatase, and convergent activation of MYC/PI3K transcriptional programs underlying enhanced sensitivity to MYC/mTOR/PI3K inhibition. This robust experimental system presents a unique framework to study lymphoid biology and therapy. Significance: Mouse models reflective of the genetic complexity and heterogeneity of human tumors remain few, including those able to recapitulate transformation to aggressive disease histologies. Herein, we model CLL transformation into RS through multiplexed in vivo gene editing, providing key insight into the pathophysiology and therapeutic vulnerabilities of transformed disease. This article is highlighted in the In This Issue feature, p. 101

9 August 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
RGRomain Guièze
Romain Guièze
LYLoïc Ysebaert
Loïc Ysebaert
DRDamien Roos-Weil
Damien Roos-Weil
LFLuc-Mathieu Fornecker
Luc-Mathieu Fornecker
EFEmmanuelle Ferrant
Emmanuelle Ferrant
PFPierre Feugier
Pierre Feugier
Richter transformation (RT) is an aggressive lymphoma occurring in patients with chronic lymphocytic leukaemia. Here we investigated the anti-CD3/anti-CD19 T-cell-engager blinatumomab after R-CHOP (i.e. rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) in patients with untreated RT of diffuse large B-cell lymphoma histology (NCT03931642). In this multicentre phase 2 study, patients without complete response (CR) after two cycles of R-CHOP were eligible to receive an 8-week blinatumomab induction via continuous vein infusion with stepwise dosing until 112 μg/day. The primary endpoint was the CR rate after blinatumomab induction and secondary endpoint included safety, response duration, progression-free and overall survival. Thirty-nine patients started the first cycle of R-CHOP, 25 of whom received blinatumomab. After blinatumomab induction, five (20%) patients achieved CR, four (16%) achieved partial response, and six (24%) were stable. Considering the entire strategy, the overall response rate in the full-analysis-set was 46% (n = 18), with CR in 14 (36%) patients. The most common treatment-emergent adverse events of all grades in the blinatumomab-safety-set included fever (36%), anaemia (24%), and lymphopaenia (24%). Cytokine release syndrome (grade 1/2) was observed in 16% and neurotoxicity in 20% of patients. Blinatumomab demonstrated encouraging anti-tumour activity (the trial met its primary endpoint) and acceptable toxicity in patients with RT.